Institute of Life Sciences, School of Science and Technology, Ahmedabad University, Ahmedabad, Gujarat, India.
Int J Nanomedicine. 2018 Mar 15;13(T-NANO 2014 Abstracts):11-13. doi: 10.2147/IJN.S124701. eCollection 2018.
Therapeutic agents aimed at inhibiting a single molecular target have not been successful in cancer therapy, but rather they impart resistance. However, multi-target inhibitors have shown promising results in circumventing the development of resistance and inducing apoptosis in cancer cells/tissues. In this study, we encapsulated doxorubicin and celecoxib in a single liposome at a ratio of 1:10. These dual drug-encapsulated liposomes showed excellent anticancer activity compared to individually encapsulated liposomes. The expression of key proteins such as AKT and COX-2 was suppressed, which suggests that doxorubicin and celecoxib synergistically inhibit multiple key signaling pathways.
旨在抑制单一分子靶点的治疗剂在癌症治疗中并未取得成功，反而赋予了肿瘤细胞耐药性。然而，多靶点抑制剂在克服耐药性的发展和诱导癌细胞/组织凋亡方面显示出了有前景的结果。在这项研究中，我们将阿霉素和塞来昔布以 1:10 的比例包封在一个脂质体中。与单独包封的脂质体相比，这些双药物包封的脂质体显示出了优异的抗癌活性。关键蛋白如 AKT 和 COX-2 的表达受到抑制，这表明阿霉素和塞来昔布协同抑制多个关键信号通路。
